Schizophrenia in adolescents

Psychoses manifested during adolescence may not have precursor symptoms in childhood (Rutter, 1967 Remschmidt, 1975a, 1975b). The subdivision according to premorbid personality and psychosocial adaptation also seems to be important in positive and negative schizophrenia in adolescence, because there is a relationship between poor premorbid adjustment and negative schizophrenia in adulthood (Andreasen and Olsen, 1982). 

The U.S. Food and Drug Administration today approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17. This is the first FDA approval of an atypical antipsychotic drug to treat either disorder in these age groups. 

Boog, G. (2004). Obstetrical complications and subsequent schizophrenia in adolescent and young adult offsprings is there a relationship Eur. J. Obstet. Gynecol. Reprod. Biol. 114 130—136. 

Quetiapine has been approved in the USA for the treatment of schizophrenia in adolescents aged 13-17 years, bipolar mania in children and adolescents aged 10-17 years, and as adjunctive therapy for treatment of major depressive disorder [107 ]. 

---

See also in sourсe #XX -- [ ]

---